AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...

AI can help design AI systems: automating architecture choices, discovering algorithms, and optimizing hardware ...

Toward the end of this decade, a choice may face the species that could reshape its interactions with intelligence itself and this choice is whether or not it shall allow highly advanced AI systems to ...

A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

The surge of AI has, for an array of users, complicated tasks such as fixing a blocked bank account, reporting fraud or ...

Nvidia's restraint — focusing on enabling the ecosystem rather than owning it — has helped cement its role as the ...

AI use in Kurdistan is surging, aiding youth employment and trade, but experts warn of privacy risks and future self-teaching ...

Recursion Pharmaceuticals (NASDAQ: RXRX), a small-cap biotech company, has one claim to fame: It currently owns the largest ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...